DCTH Stock Forecast: Delcath Systems, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Delcath Systems, Inc. hold a median 12-month price target of $27 — +43.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 98 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Delcath Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (100): The business earns solid, repeatable profits on what it owns.
Issuance (41): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DCTH stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DCTH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +43.7% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Nov 2026 | BTIG | Reiterates | Buy | $25 |
| 10 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $32 → $36 |
| 9 Nov 2026 | BTIG | Maintains | Buy | $21 → $25 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $30 → $32 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $17 → $21 |
| 26 Feb 2026 | BTIG | Maintains | Buy | $23 → $19 |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 4 Nov 2025 | BTIG | Reiterates | Buy | — |
| 21 Oct 2025 | Canaccord Genuity | Maintains | Buy | — |
| 20 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 June 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 23 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Oct 2024 | Canaccord Genuity | Maintains | Buy | $21 |
| 18 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | $22 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DCTH.
This page is one stock. Monday covers all of them.
DCTH appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DCTH vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Delcath Systems, Inc. returned +129.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DCTH analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 120.3×
- Price / sales
- 6.1×
- Price / book
- 5.0×
- EV / EBITDA
- 92.4×
Cheaper than 7% of US stocks
Cheaper than 18% of US stocks
Cheaper than 18% of US stocks
Cheaper than 3% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 737.6%
- Gross margin
- 89.8%
- Operating margin
- 5.2%
- Net margin
- —
Higher than 97% of US stocks
Higher than 96% of US stocks
Higher than 53% of US stocks
- Return on equity
- 5.4%
- Return on assets
- 2.6%
- Dividend yield
- —
Higher than 53% of US stocks
Higher than 61% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Delcath Systems, Inc. has a market value of $669.3M and an enterprise value of $567.4M.
Revenue in the twelve months to 30 June 2026: $95.4M. The latest quarter grew 20.6% year on year.
Net income over the same four quarters: $532K, a 0.6% net margin.
Diluted earnings per share, trailing twelve months: $0.01.
Free cash flow in the twelve months to 30 June 2026: $17.5M.
Trailing P/E: 120.3×; forward P/E: 70.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Delcath Systems, Inc. employs 156 people — $612K of revenue per employee.
Data provided by Twelve Data
DCTH and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DCTH’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Delcath Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DCTH
What is the DCTH stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Delcath Systems, Inc. have a median 12-month price target of $27, with estimates ranging from $25 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DCTH stock a buy right now?
Of the 5 analysts covering Delcath Systems, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Delcath Systems, Inc. 98 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DCTH?
As at 21 Nov 2026, Delcath Systems, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).
Will DCTH stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +43.7% from the last close, and Ticker Nerd's factor model ranks Delcath Systems, Inc. 98 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DCTH stock forecast for 2030?
No analyst covering Delcath Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $36 over the next 12 months.
How has DCTH stock performed over the past year?
Delcath Systems, Inc. returned +129.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Delcath Systems, Inc. do?
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes drug-device therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes drug-device therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects. Its current product portfolio includes HEPZATO KIT in the United States and CHEMOSAT in Europe, both used in hepatic delivery procedures for liver cancer care. Delcath Systems serves specialized oncology centers and medical professionals that treat patients with liver tumors, positioning its technologies within the broader medical device and specialty pharmaceutical markets. Headquartered in Queensbury, New York, Delcath Systems plays a focused role in targeted cancer treatment by combining pharmaceutical and device-based approaches for liver-directed therapy.
CEO Mr. Gerard J. Michel MBA, MS · 156 employees · United States · https://www.delcath.com